In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
出版年份 2021 全文链接
标题
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 21, Pages 11513
出版商
MDPI AG
发表日期
2021-10-27
DOI
10.3390/ijms222111513
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
- (2021) Narjes Nasiri-Ansari et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- (2021) Haleh Chehrehgosha et al. Diabetes Therapy
- New insight and potential therapy for NAFLD: CYP2E1 and flavonoids
- (2021) Kaiyue Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart
- (2021) Teoman Dogru et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload
- (2021) Riina Harjumäki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
- (2021) Nikolaos Perakakis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
- (2021) Silvie Hojná et al. BIOMEDICINE & PHARMACOTHERAPY
- Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
- (2020) Kyung-Soo Kim et al. Clinical and Molecular Hepatology
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice
- (2020) Amir Mohamed Abdelhamid et al. LIFE SCIENCES
- The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes
- (2020) Sara Guerra et al. CURRENT OPINION IN PHARMACOLOGY
- Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
- (2020) Alessandro Mantovani et al. Metabolites
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Hepatic upregulation of fetuin-A mediates acetaminophen-induced liver injury through activation of TLR4 in mice
- (2019) Kang-Yo Lee et al. BIOCHEMICAL PHARMACOLOGY
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model
- (2019) Jae-Sung Ryu et al. Journal of Biological Engineering
- The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
- (2019) Dhiren K. Patel et al. Diabetes Therapy
- Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease
- (2019) Xin Su et al. CLINICA CHIMICA ACTA
- Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
- (2019) Tamiris Ingrid Petito-da-Silva et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Cytochrome P450 1A1 (CYP1A1) Catalyzes Lipid Peroxidation of Oleic Acid-Induced HepG2 Cells
- (2018) B. Huang et al. BIOCHEMISTRY-MOSCOW
- Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease
- (2018) Cynthia Lebeaupin et al. JOURNAL OF HEPATOLOGY
- Metabolism of steroids by cytochrome P450 2C9 variants
- (2018) Tomohide Uno et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
- (2018) Ji-Won Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
- (2017) Ruth C. R. Meex et al. Nature Reviews Endocrinology
- Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis
- (2017) Xiaoyan Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance
- (2017) Max C. Petersen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
- (2016) Matthias Kern et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
- (2015) Martin C. Michel et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Conjugated linoleic acid reduces visceral and ectopic lipid accumulation and insulin resistance in chronic severe hypertriacylglycerolemia
- (2015) Hana Malinska et al. NUTRITION
- The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism
- (2015) Sílvia S. Chambel et al. Biomed Research International
- Possible involvement of nuclear factor erythroid 2-related factor 2 in the gene expression of Cyp2b10 and Cyp2a5
- (2014) Takashi Ashino et al. Redox Biology
- Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders
- (2013) Jonathan M Hazlehurst et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease
- (2012) Tung-Ming Leung et al. JOURNAL OF HEPATOLOGY
- Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats
- (2011) Kinuyo Iwata et al. Journal of Physiological Sciences
- Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
- (2010) Yusuf Yilmaz et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More